LEADER 02009nam  2200373   450 
001 9910688415803321
005 20230629185326.0
035   $a(CKB)5400000000040800
035   $a(NjHacI)995400000000040800
035   $a(EXLCZ)995400000000040800
100   $a20230629d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aTranslational research in cancer /$fedited by Sivapatham Sundaresan, Yeun-Hwa Gu
210  1$aLondon :$cIntechOpen,$d[2021]
210  4$dİ2021
215   $a1 online resource (210 pages) $cillustrations
311   $a1-78984-837-7 
320   $aIncludes bibliographical references.
330   $aTranslational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies concerning the molecular pathways involved in tumorigenesis. Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. The vast majority of cancer cases are due to environmental risk factors. Many of these environmental factors are controllable lifestyle choices. Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment through translational research. The key features of the book include: 1. New screening for the development of radioprotectors: radioprotection and anti-cancer effect of ?-Glucan (Enterococcus faecalis) 2. Translational perspective on hepatocellular carcinoma 3. Brachytherapy for endometrial cancer 4. Discovery of small molecule inhibitors for histone methyltransferases in cancer.
606   $aCancer$xResearch
615  0$aCancer$xResearch.
676   $a616.9940072
702   $aSundaresan$b Sivapatham
702   $aGu$b Yeun-Hwa
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688415803321
996   $aTranslational Research in Cancer$92826422
997   $aUNINA